Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer

Journal of Sichuan University (Medical Science)

Volumn 43, Issue 1, 2012, Pages 60-64

  Yang, Ling Yun ^a   Wang, Hong Jing ^a   Jia, Xi Biao ^a   Wang, Xue ^a   Luo, Juan ^a   Zhang, Xiao Yan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cell lines; Cisplatin resistance; MiR 130a; Ovarian cancer

Indexed keywords

EID: 84862973102     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Du Bois A, Pfisterer J. Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer, 2005;15(1):42-50. (Pubitemid 40696477)
2. Foster T, Brown TM, Chang J, et al. A review of the current evidei.ce for maintenance therapy in ovarian cancer. Gynecol Oncol, 2009;115(2), 290-301.
3. de Jongh FE, de Wit R, Verweij J, et al. Dose-dense cisplatin/paclitaxel, a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer. Eur J Cancer, 2002;38(15):2005-2013.
4. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol, 2009;112(1):275-281.
5. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 2007;33(1):9-23. (Pubitemid 46137553)
6. Lee RC, Feinbaum RL, Ambios V. The C. elegans heterochronic gene Iin-4 encodes small RNA with antisensc complementarity to lin-14. Cell, 1993;75(5):843-854. (Pubitemid 24014542)
7. He L, He X, Lim LP, et al. A miRNA component of the p53 tumour suppressor network. Nature, 2007;447(7148):1130-1134. (Pubitemid 47014436)
8. Bhattacharya R, Nicoloso M, Arvizao R, et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res, 2009;69(23):9090-9095.
9. Li Y, Guessous F, Zhang Y, et al. MiRNA-34a inhibits glioblastoma by targeting multiple oncogenes. Cancer Res, 2009;69(19):7569-7576.
10. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human miRNAs that suppress breast cancer metastasis. Nature, 2008, 451(7175), 147-152.
11. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood, 2008;111(3):1217-1226. (Pubitemid 351213403)
12. Wang XC, Tian LL, Wu HI., et al. Expression of miRNA-130a in nonsmall cell lung cancer. Am J Med Sci, 2010;340(5):385-388.
13. Xia L, Zhang D, Du R, et al. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer, 2008;123(2):372-379. (Pubitemid 351842022)
14. Kovalchuk O, Filkowski J, Meservy J, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther, 2008;7(7):2152-2159.
15. Cui XY, Guo YJ, Yao HR. Analysis of microRNA in drugresistant breast cancer cell line MCF-7/ADR. Nan Fang Yi Ke DaXue Xue Bao, 2008;28(10):1813-1815.
16. Troost J, Lindenmaier H, Haefeli WE, et al. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrugresistant cells. Mol Pharmacol, 2004;66(5):1332-1339. (Pubitemid 39411074)
17. Tarke K, Jourdan M, Veyrune JL, et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptoic factor for myeloma cells. Br J Haematol, 2004;125(3):373-382. (Pubitemid 38621770)